C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics

American Journal of Hematology

Volumn 85, Issue 6, 2010, Pages 426-430

  Lu, Ying ^a,b   Chen, Wengang ^a   Chen, Wei ^a,c   Stein, Anthony ^a   Weiss, Lawrence M ^a   Huang, Qin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NINGBO FIRST HOSPITAL   (China)

^c The Affiliated Sir Run Run Hospital of Nanjing Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA; FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; FEMALE; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; WILD TYPE;

ACUTE DISEASE; ADULT; AGED; CCAAT-ENHANCER-BINDING PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RISK; YOUNG ADULT;

EID: 77953047175     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21706     Document Type: Article

References (29)

1. Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukemia with recurrent genetic abnormalities. Swerdlow S,Campo E,Harris NL,Jaffe ES,Pileri SA,Stein H. et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon: IARC Press; 2008. 120-123.
2. Tenen DG, Hromas R, Licht JD, et al. Transcription factors, normal myeloid development, and leukemia. Blood 1997;90:489-519. (Pubitemid 27299089)
3. Rosmarin AG, Yang Z, Resendes KK. Transcription regulation in myelopoiesis: hematopoietic fate choice, myeloid differentiation, and leukemogenesis. Exp Hematol 2005;33:131-143. (Pubitemid 40164893)
4. Friedman AD, Keefer JR, Kummalue T, et al. Regulation of granulocyte and monocyte differentiation by CCAAT/enhance binding protein a. Blood Cells Mol Dis 2003;31:338-341.
5. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein a in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002;99:1332-1340.
6. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic signification of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-2723.
7. Waaalwijk Van Waalwijk Van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematology 2003;4:31-40.
8. Kaeferstein A, Krug U, Tiesmeier J, et al. The emergence of a C/EBPA mutation in the clonal evolution of MDS towards secondary AML. Leukemia 2003;17:343-349.
9. Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001;7:444-451.
10. Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008;35:346-355.
11. Schlenk RF, Döhner K, Krauter J, et al. German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918.
12. Tada Y, Brena RM, Hackanson B, et al. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 2006;98:396-406.
13. Bennett KL, Hackanson B, Smith LT, et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 2007;67:4657-4664.
14. Chim CS, Wong AS, Kwong YL. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J Haematol 2002;119:988-990.
15. Agrawal S, Hofmann WK, Tidow N, et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 2007;109:3895-3905.
16. Figueroa ME, Wouters BJ, Skrabanek L, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009;113:2795-2804.
17. Jost E, Do ON, Wilop S, et al. Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. Leuk Res 2009;33:443-449.
18. Snaddon J, Smith ML, Neat M, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1and M2. Genes Chromosomes Cancer 2003;37:72-78.
19. Huang Q, Ai L, Zhang ZY, Fan CY, Weiss LM. Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. Mod Pathol 2004;17:416-422.
20. Huang Q, Chen W, Gaal KK, et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 2008;142:489-492.
21. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002;30:48-58.
22. Leroy H, Roumier C, Huyghe P, et al. CEBPA point mutations in hematological malignancies. Leukemia 2005;19:329-334.
23. Suela J, Alvarez S, Cifuentes F, et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007;21:1224-1231.
24. Fröhling S, Schlenk RF, Stolze I, et al. Mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624-633.
25. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005;11:1372-1379.
26. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380. (Pubitemid 35434129)
27. Castilla LH. C/EBPalpha in leukemogenesis: a matter of being in the right place with the right signals. Cancer Cell 2008;13:289-291.
28. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:5078-5087.
29. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009;113:5090-5093.